| Literature DB >> 34377001 |
Zhiyuan Wu1, Yufeng Liang1, Yunlong Zuo1, Yufen Xu2, Hanran Mai2, Lei Pi2, Di Che2, Xiaoqiong Gu2.
Abstract
PURPOSE: Accumulating evidence demonstrates that genetic susceptibility genes can be used as biomarkers to assess sepsis susceptibility, and genetic variation is associated with susceptibility and clinical outcomes in patients with sepsis and inflammatory disease. Although studies have shown that the lncRNA CCAT2 is involved in inflammatory diseases, it remains unclear whether CCAT2 gene polymorphisms are associated with susceptibility to inflammatory diseases, such as sepsis, in children.Entities:
Keywords: lncRNA CCAT2; polymorphism; sepsis; susceptibility
Year: 2021 PMID: 34377001 PMCID: PMC8349528 DOI: 10.2147/IDR.S311717
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Frequency Distribution of Selected Characteristics in Sepsis Cases and Healthy Controls
| Variables | Cases (n = 474) | Controls (n = 678) | |||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| Age range, month | 1–180 | 1–168 | |||
| Mean ± SD | 35.04 ±34.26 | 35.53±29.37 | 0.1811 | ||
| ≤60 | 403 | 85.02 | 595 | 87.76 | |
| >60 | 71 | 14.98 | 83 | 12.24 | |
| Male | 301 | 63.5 | 399 | 58.85 | 0.111 |
| Female | 173 | 36.5 | 279 | 41.15 | |
| Sepsis | 389 | 82.07 | NA | ||
| Septic shock | 85 | 17.93 | NA | ||
| Survivors | 394 | 83.12 | NA | ||
| Non-survivors | 80 | 16.88 | NA | ||
| 1–2 | 276 | 74.39 | NA | ||
| 3 or more | 95 | 25.61 | NA | ||
| Lung infection | 278 | 58.65 | NA | ||
| Brain infection | 36 | 7.59 | NA | ||
| Primary bloodstream infection | 35 | 7.38 | NA | ||
| Abdominal infection | 28 | 5.91 | NA | ||
| Respiratory infection | 18 | 3.8 | NA | ||
| Urinary tract infection | 8 | 1.69 | NA | ||
| Others | 71 | 14.98 | NA | ||
| Gram-positive | 241 | 50.85 | NA | ||
| Gram-negative | 117 | 24.68 | NA | ||
| Mixed Gram-negative and -positive | 22 | 4.64 | NA | ||
| Fungus | 18 | 3.8 | NA | ||
| Polymicrobial | 41 | 8.65 | NA | ||
| Negative blood culture | 35 | 7.38 | NA | ||
Notes: aTwo-sided χ2 test for distributions between Sepsis patients cases and controls.
Genotype Frequency Distribution of CCAT2 in Sepsis Cases and Healthy Controls
| genotype | Cases (N = 474) | Controls (N =678) | P-valuea | OR (95% CI) | P-value | Adjusted OR (95% CI) | P-valueb |
|---|---|---|---|---|---|---|---|
| TT | 135(28.48) | 240(35.40) | 0.0426 | 1.000 | 1.000 | ||
| TG | 243(51.27) | 320(47.20) | |||||
| GG | 96(20.25) | 118(17.40) | |||||
| Dominant | 339(71.52) | 438(64.60) | |||||
| Recessive | 378(79.75) | 560(82.60) | 0.2225 | 1.205(0.893–1.626) | 0.2215 | 1.215(0.900–1.639) | 0.2039 |
Notes: aχ2 tests were used to determine differences in genotype distributions between the children with sepsis and the controls. b Adjusted for age and gender. Statistically significant values are shown in bold (P<0.05).
Abbreviations: OR, odds ratio; HWE, Hardy–Weinberg equation.
Stratification Analysis of Susceptibility in Sepsis Patients
| Variables | TT | TG/GG | P-value | OR (95% CI) | P-value | Adjusted OR (95% CI) | P-valuea |
|---|---|---|---|---|---|---|---|
| Patients/controls | |||||||
| ≤60 | 113/209 | 290/386 | |||||
| >60 | 22/31 | 49/52 | 0.4066 | 1.328(0.678–2.599) | 0.4079 | 1.382(0.700–2.729) | 0.3516 |
| Male | 78/135 | 223/264 | |||||
| Female | 57/105 | 116/174 | 0.3113 | 1.228(0.824–1.830) | 0.3128 | 1.241(0.832–1.852) | 0.2898 |
| Sepsis | 114/240 | 275/438 | |||||
| Septic shock | 21/240 | 64/438 | 0.0448 | 1.670(0.995–2.802) | 0.0521 | 1.641(0.977–2.756) | 0.0612 |
| Survivors | 118/240 | 276/438 | 0.0671 | 1.282(0.981–1.674) | 0.0685 | 1.265(0.968–1.653) | 0.0852 |
| Non-survivors | 17/240 | 63/438 | |||||
| 1–2 | 75/240 | 201/438 | |||||
| 3 or more | 26/240 | 69/438 | 0.1168 | 1.454(0.902–2.344) | 0.1247 | 1.453(0.900–2.347) | 0.1265 |
Notes: aAdjusted for age and gender. Statistically significant values are shown in bold (P<0.05).
Abbreviation: OR, odds ratio.
False Positive Report Probability Values for Associations Between the Risk of Sepsis and CCAT2 Polymorphism Genotype
| Genotype/Allele | OR (95% CI) | p-valuea | Statistical powerb | Prior Probability | ||||
|---|---|---|---|---|---|---|---|---|
| 0.25 | 0.1 | 0.01 | 0.001 | 0.0001 | ||||
| TG Vs TT | 1.350(1.032–1.766) | 0.0287 | 0.883 | 0.226 | 0.763 | 0.97 | 0.997 | |
| GG Vs TT | 1.446(1.027–2.0360) | 0.0345 | 0.735 | 0.297 | 0.823 | 0.979 | 0.998 | |
| GG/TG Vs TT | 1.376(1.067–1.774) | 0.0138 | 0.741 | 0.648 | 0.949 | 0.995 | ||
| ≤60 | 1.390(1.056–1.829) | 0.0190 | 0.703 | 0.728 | 0.964 | 0.996 | ||
| Male | 1.462(1.050–2.035) | 0.0245 | 0.561 | 0.282 | 0.812 | 0.978 | 0.998 | |
| Non-survivors | 2.031(1.162–3.549) | 0.0129 | 0.156 | 0.426 | 0.891 | 0.988 | 0.999 | |
| 1–2 | 1.468(1.079–1.999) | 0.0146 | 0.555 | 0.722 | 0.963 | 0.996 | ||
Notes: aThe χ2 test was used to calculate the genotype frequency distributions. bThe statistical power was calculated using the number of observations and the OR and P values. Statistically significant values are shown in bold (P < 0.2)
Abbreviation: OR, odds ratio.